Berlin - SPecific Acute Treatment in Ischemic or hAemorrhagic Stroke With Long Term Follow-up (B-SPATIAL)

September 10, 2022 updated by: Heinrich J Audebert, Charite University, Berlin, Germany

Berlin - Specific Acute Treatment in Ischemic or Haemorrhagic Stroke With Long Term Follow-up

The B-SPATIAL-Registry will provide a tool of quality assessment for stroke specific Treatments such as endovascular treatment. It will also enable the participating hospitals to compare the quality of care of their facility. At the same time, B-SPATIAL will provide an opportunity of scientific evaluation of new therapeutic procedures or specific treatments in stroke (i.e. reversal of oral anticoagulation in intracerebral hemorrhage or intravenous thrombolysis), not sufficiently investigated so far. Finally, the B-SPATIAL Registry will allow for an identification of key quality indicators that assure valid quality assessment aiming at a reduced documentation load for future quality management.

Study Overview

Status

Completed

Conditions

Detailed Description

  1. Background

    Quality assessment of acute stroke care is organized in regional stroke registries in Germany - for the federal state of Berlin in the Berlin Stroke Registry (BSR). The current documentation of the Berlin Stroke Registry is focused on the documentation of process quality in participating hospitals.

    So far, outcome quality is only assessed by surrogate parameters such as complications and mortality during in-hospital stay. However, according to consensus recommendations, disability-free survival versus death and dependency is the most important outcome measure after acute stroke. Because of the high variability of the clinical course after stroke, this outcome is generally assessed after three months by using the modified Rankin Scale (mRS).

  2. Motivation

    In early 2015, several published trials showed that mechanical thrombectomy improves the prognosis of ischemic stroke patients with acute large artery occlusion of proximal brain supplying arteries. Currently, this invasive catheter based treatment is not available in many hospitals with acute Stroke Unit. It is likely that the quality of technical procedures depends on the expertise and experience of treating interventionalists. Current studies suggest a close relationship between effectiveness of the approach and time to treatment, similar to intravenous thrombolysis. This time dependency makes prehospital triage more challenging because selection of the appropriate facility is likely to influence patient outcome.

    Intracerebral hemorrhage (ICH) is less frequent than ischemic stroke but is associated with worse prognosis. Recent studies suggest that blood pressure lowering may improve prognosis if started during the hyperacute phase of ICH. With limited scientific evidence, many patients undergo neurosurgical intervention. It remains unclear whether delivery of hemorrhagic stroke patients to hospitals with neurosurgery leads to better outcome.

    Hence, pre-hospital care with delivery to more or less specialized clinical facilities may have a crucial impact for both subtypes of stroke. The introduction of specialized stroke ambulances (Stroke Emergency Mobiles, STEMOs) opens new avenues for pre-hospital stroke diagnosis, treatment and patient triage. The effects of STEMO care are planned to be assessed by the parallel B-PROUD-Study (NCT02869386).

  3. Purpose

    The B-SPATIAL-Registry will provide a tool of quality assessment for new specific treatments. It will also enable the participating hospitals to compare the quality of care of their own facility.

    Because this registry represents an quality monitoring initiative, the telephone follow-up is collected with an opt-out solution, allowing to decline participation after the patients are informed on the follow-up telephone call at discharge and through a letter send one month prior to the actual call. As written informed consent is not required, this method will facilitate a high follow-up rate particularly in patients with severe neurological deficits or treated in non-academic hospitals.

    In B-SPATIAL we want to identify key quality indicators that assure valid quality assessment despite reduced documentation load in future quality management.

    Specific Aims of the registry:

    • Assessment of proportions of patients receiving specific treatments (based on total number of eligible)
    • Evaluation of treatment specific indicators for process quality including pre-hospital care
    • Evaluation of outcome quality (survival, level of disability and quality of life after 3 months)

    Pre-specified analyses:

    Ischemic stroke

    • Intravenous hospital based tPA rate in treatment candidates
    • Time to treatment in intravenous tPA
    • Rate of secondary interhospital referral
    • Proportions of patients receiving endovascular thrombectomy
    • Time to groin puncture and reperfusion in patients with endovascular thrombectomy
    • Proportions of used devices
    • Proportions of patients with general/non general anesthesia (conscious sedation)
    • Secondary intracranial hemorrhage
    • Functional outcome according to mRS at 3 months

    Hemorrhagic stroke

    • Time to start of intravenous antihypertensive treatment
    • Time to start of PCC in patients with OAC or specific reversal of NOACs
    • Rate of surgical treatments
    • Rate of secondary interhospital referral
    • Enlargement and final volume of ICH
    • Functional outcome according to mRS at 3 months

    Data sources

    The documentation will include pre-hospital, in-hospital and post-discharge processes such as:

    • Emergency medical service (EMS)
    • Acute in-hospital stay
    • Follow-up (first choice: telephone, second choice: written questionnaire, third choice: FU regarding vital status from registration offices)
  4. Patients

    In order to ensure valid analysis of treatment rates in participating hospitals, patients will be included according to the following inclusion criteria:

    • Patients with hospital main discharge diagnoses according to ICD 10: Ischemic stroke (I63) or TIA (G45.0-G45.3 and G45.5-G45.9, respectively) and

      • Onset of symptoms within 6 hours of hospital arrival
      • In patients with TIA diagnosis: Persistent neurological symptoms at hospital arrival (emergency department documentation)
    • Patients with main discharge diagnosis of intracranial hemorrhage and hospital admission within 6 hours of stroke onset.
    • Patients with other main discharge diagnoses and documented intravenous thrombolysis (OPS 8-020.8) in order to monitor the treatment rate of stroke mimics
  5. Data documentation

    • Data will be entered in all participating hospitals via remote access to the databank
    • Data will be entered with pseudonyms but identification will only be possible in local hospitals via register-logs that will be safely stored in the hospitals.
  6. Databank characteristics

    • For data entry, we will use the REDcap databank software with access from all participating hospitals.
    • Dedicated computers will be used and safely stored in participating hospitals. Encryption and password algorithms will protect the remote access to the databank.
    • The registry databank will be stored and hosted on a protected server of the Charité IT department.
    • For statistical evaluation, the REDcap databank will be exported in an SPSS-based data format, stored on the server of the Center for Stroke Research Berlin (CSB).
  7. Responsibilities

    • Data entry: Study nurses in participating hospitals
    • Databank in Charité IT-center: Charité IT department and databank manager of the Clinical Research Units
    • Scientific evaluation: PI of CSB (Jessica L.Rohmann in cooperation with Heinrich J. Audebert, Martin Ebinger and Christian Nolte)

Study Type

Observational

Enrollment (Actual)

15246

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany
        • Center for Stroke Research Berlin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Stroke patients (ischemic and haemorrhagic)

Description

Inclusion criteria:

  1. Patients with hospital main discharge diagnoses according to ICD 10: Ischemic stroke (I63) or TIA (G45.0-G45.3 and G45.5-G45.9, respectively) and

    • Onset of symptoms within 6 hours of hospital arrival
    • In patients with TIA diagnosis: Persistent neurological symptoms at hospital arrival (emergency department documentation)
  2. Patients with main discharge diagnosis of intracranial hemorrhage and symptom onset within 6 hours of hospital admission
  3. Patients with other main discharge diagnoses and documented intravenous thrombolysis (OPS 8-020.8) in order to monitor the treatment rate of stroke mimics

Exclusion Critera:

  • Symptom remission before EMS arrival or hospital arrival (if no EMS Transport)
  • Primary subarachnoid hemorrhage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Rankin Scale
Time Frame: 3 months
Assessment of functional outcome over the entire range of the modified Rankin Scale
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Actual)

April 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

January 19, 2017

First Submitted That Met QC Criteria

January 20, 2017

First Posted (Estimate)

January 23, 2017

Study Record Updates

Last Update Posted (Actual)

September 13, 2022

Last Update Submitted That Met QC Criteria

September 10, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

3
Subscribe